Full Press Release Details
Armata Pharmaceuticals Announces Third Quarter 2024 Results and
Provides Corporate Update
LOS ANGELES, CA, November 13, 2024 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its third quarter ended September 30, 2024, and provided a corporate update.
Third Quarter 2024 and Recent Developments:
"During the third quarter, we completed enrollment of our Phase 2 Tailwind study of inhaled AP-PA02 in NCFB patients with chronic P. aeruginosa infection, and remain on-track to report topline data from this study by the end of this year," stated Dr. Deborah Birx, Chief Executive Officer of Armata. "This will mark our second Phase 2 data readout for inhaled AP-PA02, following prior successful evaluation in patients with cystic fibrosis in the Phase 1b/2a SWARM-P.a. clinical trial last year. We plan to meet with the U.S. FDA to align on the design of a pivotal Phase 3 bronchiectasis study for inhaled AP-PA02 as a pulmonary disease therapeutic which we are working towards initiating in 2025."
"Additionally, we have completed enrollment of our Phase 1b/2a diSArm study evaluating intravenous AP-SA02 as a potential treatment for S. aureus bacteremia. The high purity of Armata's intravenously-administered phage drug products enabled dose escalation to 2E11 PFU every 24 hours for five days, which was well-tolerated. We look forward to topline data in the first quarter of 2025 that should inform the optimal dose of AP-SA02 to be evaluated in a larger definitive efficacy study that we are planning to initiate in 2025."
"With two Phase 2 data readouts expected near-term, we believe we continue to add to the body of evidence demonstrating the potential of phage therapy, either as an alternative to or in combination with current standard of care antibiotics, to combat antibiotic-resistant and difficult-to-treat bacterial infections. I am delighted with our progress to date, and look forward to potential major value inflection points in 2025 and beyond," Dr. Birx concluded.
Third Quarter 2024 Financial Results
Grant Revenue. The Company recognized grant revenue of $3.0 million for the three months ended September 30, 2024 as compared to $1.2 million in the comparable period in 2023, which represents MTEC's share of the costs incurred for the Company's AP-SA02 program for the treatment of S. aureus bacteremia.
Research and Development. Research and development expenses for the three months ended September 30, 2024 were approximately $9.5 million as compared to approximately $8.0 million for the comparable period in 2023. The Company continues to invest in clinical related expenses associated with its primary development programs.
General and Administrative. General and administrative expenses for the three months ended September 30, 2024 were approximately $3.2 million as compared to approximately $3.6 million for the comparable period in 2023. The decrease was mainly related to a decrease of $1.0 million in professional services during the third quarter of 2024, offset in part by an increase of $0.6 million in personnel related expenses.
Loss from Operations. Loss from operations for the three months ended September 30, 2024 was approximately $9.8 million as compared to a loss from operations of approximately $10.3 million for the comparable period in 2023.
Net Loss. The net loss for the third quarter of 2024 was $5.5 million, or $0.15 per share on both a basic and diluted basis, as compared to a net loss of $31.2 million, or $0.86 per share on both a basic and diluted basis, for the comparable period in 2023. The net loss for the quarter ended September 30, 2024 included non-cash gain from changes in fair value of convertible debt of $6.9 million, as compared to $15.8 million loss from changes in fair value of convertible debt for the quarter ended September 30, 2023.
Cash and Equivalents. As of September 30, 2024, Armata held approximately $17.1 million of unrestricted cash and cash equivalents, as compared to $13.5 million as of December 31, 2023.
As of November 13, 2024, there were approximately 36.2 million common shares outstanding.
About Armata Pharmaceuticals, Inc.
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.
Forward Looking Statements
This communication contains "forward-looking" statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to Armata's future financial performance and involve known and unknown risks, uncertainties and other factors which may cause Armata's actual results, performance or events to be materially different from any future results, performance or events expressed or implied by the forward-looking statements. In some cases, you can identify these statements by terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions. These forward-looking statements reflect management's beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this communication and are subject to risks and uncertainties including risks related to Armata's development of bacteriophage-based therapies; ability to staff and maintain its production facilities under fully compliant current Good Manufacturing Practices; ability to meet anticipated milestones in the development and testing of the relevant product; ability to be a leader in the development of phage-based therapeutics; ability to achieve its vision, including improvements through engineering and success of clinical trials; ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata's estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption "Risk Factors" and elsewhere in Armata's filings and reports with the SEC, including in Armata's Annual Report on Form 10-K, filed with the SEC on March 21, 2024, and in its subsequent filings with the SEC.
Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
LifeSci Advisors, LLC
Armata Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
| September 30, 2024 | December 31, 2023 | ||||||
| Assets | |||||||
| Current assets | |||||||
| Cash and cash equivalents | $ | 17,141 | $ | 13,523 | |||
| Prepaid expenses and other current assets | 3,029 | 2,265 | |||||
| Other receivables | 2,219 | 3,363 | |||||
| Total current assets | 22,389 | 19,151 | |||||
| Property and equipment, net | 13,616 | 12,559 | |||||
| Operating lease right-of-use asset | 42,251 | 44,717 | |||||
| Intangible assets, net | 13,746 | 13,746 | |||||
| Other long term assets | 6,235 | 8,190 | |||||
| Total assets | $ | 98,237 | $ | 98,363 | |||
| Liabilities and stockholders' deficit | |||||||
| Accounts payable, accrued and other current liabilities | 10,801 | 16,461 | |||||
| Convertible debt, current | 41,357 | - | |||||
| Term debt, current | 66,046 | - | |||||
| Total current liabilities | $ | 118,204 | $ | 16,461 | |||
| Convertible debt, non-current | - | 58,633 | |||||
| Term debt, non-current | - | 23,674 | |||||
| Operating lease liabilities, net of current portion | 27,929 | 28,583 | |||||
| Deferred tax liability | 3,077 | 3,077 | |||||
| Total liabilities | 149,210 | 130,428 | |||||
| Stockholders' deficit | (50,973) | (32,065) | |||||
| Total liabilities and stockholders' deficit | $ | 98,237 | $ | 98,363 |
Armata Pharmaceuticals, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
| Three Months Ended | Nine Months Ended | ||||||||||||
| September 30, | September 30, | ||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||
| Grant revenue | $ | 2,973 | $ | 1,225 | $ | 3,939 | $ | 3,001 | |||||
| Operating expenses: | |||||||||||||
| Research and development | 9,485 | 7,978 | 25,975 | 25,842 | |||||||||
| General and administrative | 3,244 | 3,583 | 9,861 | 8,470 | |||||||||
| Total operating expenses | 12,729 | 11,561 | 35,836 | 34,312 | |||||||||
| Operating loss | (9,756) | (10,336) | (31,897) | (31,311) | |||||||||
| Interest income | 294 | 47 | 567 | 111 | |||||||||
| Interest expense | (2,923) | (1,176) | (7,462) | (1,176) | |||||||||
| Change in fair value of convertible debt | 6,904 | (15,833) | 17,276 | (12,959) | |||||||||
| Loss on convertible debt extinguishment | - | (3,863) | - | (3,863) | |||||||||
| Net loss | $ | (5,481) | $ | (31,161) | $ | (21,516) | $ | (49,198) | |||||
| Per share information: | |||||||||||||
| Net loss per share, basic and diluted | $ | (0.15) | $ | (0.86) | $ | (0.60) | $ | (1.36) | |||||
| Weighted average shares outstanding, basic and diluted | 36,180,124 | 36,086,990 | 36,153,388 | 36,067,025 |
Armata Pharmaceuticals, Inc.
Condensed Consolidated Statements of Cash Flows
| Nine Months Ended September 30, | |||||||
| 2024 | 2023 | ||||||
| Operating activities: | |||||||
| Net loss | $ | (21,516) | $ | (49,198) | |||
| Adjustments required to reconcile net loss to net cash used in operating activities: | |||||||
| Depreciation and amortization expense | 945 | 679 | |||||
| Stock-based compensation expense | 2,539 | 745 | |||||
| Change in fair value of convertible debt | (17,276) | 12,959 | |||||
| Non-cash interest expense | 7,483 | 1,176 | |||||
| Loss on convertible debt extinguishment | - | 3,863 | |||||
| Change in right-of-use asset | 1,489 | 662 | |||||
| Changes in operating assets and liabilities: | (3,288) | (10,203) | |||||
| Net cash used in operating activities | (29,624) | (39,317) | |||||
| Investing activities: | |||||||
| Purchases of property and equipment | (1,956) | (5,744) | |||||
| Net cash used in investing activities | (1,956) | (5,744) | |||||
| Financing activities: | |||||||
| Proceeds from issuance of convertible debt, net of issuance costs | - | 29,101 | |||||
| Proceeds from issuance of term debt, net of issuance costs | 34,889 | 24,925 | |||||
| Payments for taxes related to net share settlement of equity awards | (61) | - | |||||
| Proceeds from exercise of stock options | 130 | 5 | |||||
| Net cash provided by financing activities | 34,958 | 54,031 | |||||
| Net increase in cash, cash equivalents and restricted cash | 3,378 | 8,970 | |||||
| Cash, cash equivalents and restricted cash, beginning of period | 19,243 | 20,812 | |||||
| Cash, cash equivalents and restricted cash, end of period | $ | 22,621 | $ | 29,782 |
| Nine Months Ended September 30, | ||||||
| 2024 | 2023 | |||||
| Cash and cash equivalents | $ | 17,141 | $ | 23,958 | ||
| Restricted cash | 5,480 | 5,824 | ||||
| Cash, cash equivalents and restricted cash, end of period | $ | 22,621 | $ | 29,782 |